हिंदी में पढ़ें
Income Tax Calculator
Personal Loan Calculator
Car Loan Calculator
Home Loan Calculator
MF Returns Calculator
Divis Lab News
Divi's Lab Share price: Anand Rathi positive, says BUY, target price Rs 4095 | Here is what you need to know
Mon, Dec 07, 2020
Divi's Laboratories is one of the leading manufacturers of Active Pharmaceutical Ingredients (API) in the world. Growth prospects of Divi’s look decent with favorable traits in the API industry due to supply chain readjustments/ diversification from China into other countries including India amid the COVID-19 pandemic. As global players are looking to reduce dependency on China and preferring India, companies like Divi’s remain well placed to capitalize on such opportunities. Also, in custom synthesis, the company is connected with several pharma giants and looks to benefit as India may tap opportunities in terms of the consumption of custom synthesis.
Macquarie says Dr Reddy's, Cipla and Divi's Labs are top stock picks as Nifty Pharma trades at 12% premium to Nifty
Wed, Nov 11, 2020
Nifty Pharma now trades at a 12% premium to Nifty, this compares to a long-term average premium of 38%. Macquarie stays positive on India pharma companies. Dr Reddy's, Cipla and Divi's Labs are their top stock picks in large-cap pharma space while Syngene, Solara and Jubilant life are preferred mid-cap picks.
Divi’s Lab surges 4% afterTelangana unit completes USFDA inspection with no observations
Thu, May 17, 2018
Divi’s Laboratories rallied over 4 per cent after a unit in Telangana did not receive any 483 observations following an inspection by the US Food and Drug Administration. Reacting to this, the stock gained 4 per cent to hit an intraday high of Rs 1213.
Divi's laboratories drops over 10% on USFDA reports
Mon, Dec 26, 2016
Pharmaceutical major Divi's Laboratories Ltd continued to fall on Monday with the stock cracking over 10%, or Rs 85.75 per share.